Table 2 The relationship between clinicopathological characteristics and an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer
From: Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer
GPS 0 ( n =51) | GPS 1 ( n =39) | GPS 2 ( n =6) | P -value | |
|---|---|---|---|---|
Age (⩽50/>50years) | 10/41 | 10/29 | 1/5 | 0.751 |
Prior cytotoxic chemotherapies | ||||
(0/⩾1) | 36/15 | 32/7 | 4/2 | 0.409 |
Metastatic site | ||||
(Nonvisceral/visceral/both) | 24/9/18 | 16/5/18 | 3/0/3 | 0.684 |
Oestrogen receptor status | ||||
(positive/negative) | 27/18 | 30/9 | 6/0 | 0.061 |
Disease-free interval | ||||
(>2/⩽2 years) | 35/16 | 27/12 | 5/1 | 0.756 |
White cell count | ||||
(⩽11/>11 × 109 l−1) | 40/1 | 28/2 | 6/0 | 0.58 |
Haemoglobin | ||||
(⩾12/<12 g dl−1) | 26/14 | 18/12 | 2/4 | 0.334 |
Treatment | ||||
(Herceptin/active/supportive) | 9/42/0 | 2/33/4 | 0/6/0 | 0.044 |
Survival (months) | 23.8 | 12.7 | 1.2 | |
(20.2–27.5) | (5.1–20.3) | (0.7–10.4) | <0.001 | |
